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Abstract Differences in the biological properties of the
Clostridium perfringens phospholipase C (K-toxin) and the C.
bifermentans phospholipase C (Cbp) have been attributed to
differences in their carboxy-terminal domains. Three residues in
the carboxy-terminal domain of K-toxin, which have been
proposed to play a role in membrane recognition (D269, Y331
and F334), are not conserved in Cbp (Y, L and I respectively). We
have characterised D269Y, Y331L and F334I variant forms of
K-toxin. Variant D269Y had reduced phospholipase C activity
towards aggregated egg yolk phospholipid but increased
haemolytic and cytotoxic activity. Variants Y331L and F334I
showed a reduction in phospholipase C, haemolytic and cytotoxic
activities indicating that these substitutions contribute to the
reduced haemolytic and cytotoxic activity of Cbp. ß 2001 Pub-
lished by Elsevier Science B.V. on behalf of the Federation of
European Biochemical Societies.
Key words: Phospholipase C; Membrane binding;
Site-directed mutant
1. Introduction
The zinc-metallophospholipases C are a group of related
proteins produced by Gram-positive bacteria including Clos-
tridium perfringens, Clostridium novyi, Clostridium bifermen-
tans, Bacillus cereus and Listeria monocytogenes. Some of
these enzymes play key roles in the pathogenesis of disease
[1]. For example, the phospholipase C (K-toxin) produced by
C. perfringens is the major virulence factor in gas gangrene
[2,3]. The K-toxin hydrolyses phosphatidylcholine and sphin-
gomyelin in both monodispersed and membrane-packed
forms [4^6]. Unlike many zinc-metallophospholipases C, K-
toxin is haemolytic, cytotoxic and myotoxic. Myotoxicity
caused by K-toxin is complex, and depends not only on dam-
age to the muscle ¢bres, but also on the e¡ects of the toxin on
the haemostatic system [7,8].
Many of these biological activities are a direct consequence
of the hydrolysis of membrane phospholipids [6,9]. However,
there is also evidence that haemolysis and cytotoxicity occur
as a result of the activation of endogenous membrane phos-
pholipases by K-toxin [10,11]. The mechanism by which these
endogenous phospholipases are activated is not clear and
could be mediated by the products of limited hydrolysis of
membrane phospholipids [10,12] or by the binding of K-toxin
to a cell surface GTP protein receptor [11].
Considerable insight into the mode of action of K-toxin has
been provided by the crystal structure. This revealed an ami-
no-terminal domain containing the active site and a carboxy-
terminal domain which was structurally homologous to eu-
karyotic C2 domains, and allowed binding to membrane
phospholipids [13,14]. This model explained why the isolated
amino-terminal domain retained phospholipase C activity but
was devoid of haemolytic, cytotoxic and myotoxic activities
[7,15,16]. The recognition of membrane phospholipids by the
carboxy-terminal of K-toxin is thought to involve both the
insertion of surface-exposed hydrophobic residues into the
lipid bilayer, and the Ca2-mediated recognition of phospho-
lipid head groups [13,14]. Some amino acids proposed to play
a key role in the recognition of membrane phospholipids
(D269, Y331 and F334) are not conserved in the phospholipase
C produced by C. bifermentans (Cbp), a structurally related
enzyme which displays weak haemolytic, cytotoxic and myo-
toxic activities [7,16,17]. These di¡erences might therefore
provide a molecular explanation for the profound di¡erences
in the properties of these related enzymes. The aim of this
work was to determine the roles of D269, Y331 and F334 in
the biological activities of K-toxin by replacing them individ-
ually with their counterparts in C. bifermentans Cbp.
2. Materials and methods
2.1. Enzymes and chemicals
Unless stated enzymes were obtained from Sigma-Aldrich (Poole,
UK). Materials for protein puri¢cation were obtained from Amer-
sham-Pharmacia Biotech UK Ltd (Little Chalfont, UK). Materials
for DNA puri¢cation were obtained from Roche Molecular Biochem-
icals (Lewes, UK).
2.2. DNA cloning and nucleotide sequencing
Oligonucleotides (K-toxinFWD 5P-GCTTGGGGCCCAAAATT-
AACGGGGGATATA-3P or 5P-CTAGGAGCTCAGGGGAGAT-
TAATACTTGA-3P and K-toxinREV 5P-TGCTCTAGATTATTTTA-
TATTATAAGTTGA-3P or 5P-CTAGTCTAGATTATTTTATATTA-
TAAGT-3P) were designed from the nucleotide sequence of the
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K-toxin gene of C. perfringens NCTC 8237 [18]. Unique restriction
sites (XbaI, DraII or SacI) introduced are shown underlined. Other
oligonucleotides contained nucleotide sequence changes to introduce
single amino acid changes (D269YFWD 5P-GGTGAGAAATAT-
GCTGGAACAGATGAC-3P ; D269YREV 5P-GTCATCTGTTCCTG-
CATATTTCTCACC-3P ; Y331LFWD 5P-AGAAAAAGAAAATTAA-
CAGCATTCTC-3P ; Y331LREV 5P-GAGAATGCTGTTAATTTT-
CTTTTTCT-3P ; F334IFWD 5P-ATACAGCAATATCAGATGCT-
TAT-3P ; F334IREV 5P-ATAAGCATCTGATATTGCTGTAT-3P).
The oligonucleotides were used in the PCR (30 cycles of 94‡C, 60 s;
45‡C, 60 s; 72‡C, 90 s) with plasmid pKSK3 [19] as template DNA.
Two PCR products were generated, which encoded the mutated se-
quence and the region of the cpa gene 5P and 3P (respectively) to the
mutation. These PCR products were used in a PCR reaction without
the further addition of template DNA or oligonucleotide primers, to
generate the mutated cpa gene. The D269Y coding region was cloned
into plasmid KPROM27 [17] and the Y331L and F334I coding regions
were cloned into plasmid pTrc99a (Amersham-Pharmacia Biotech UK
Ltd). The plasmids were transformed into Escherichia coli DH5K [20]
and transformants containing recombinant plasmids identi¢ed using
the PCR. Plasmid DNA was isolated and nucleotide sequenced using
dithiothreitol chemistry, as detailed previously [17].
2.3. Expression and puri¢cation of K-toxin proteins
Wild-type K-toxin or variant D269Y were expressed in E. coli and
isolated from the periplasmic space [18,19]. Expression of variants
Y331L or F334I was induced with 3 mM IPTG with further growth
for 5 h. Protein was isolated from the periplasmic space of the re-
combinant E. coli [18,19].
The wild-type or variant proteins were puri¢ed using FPLC column
chromatography [17] and analysed using SDS^PAGE (10^15% gels;
(Amersham-Pharmacia Biotech UK Ltd PhastSystem) after staining
with Coomassie blue R250. Protein concentrations were determined
using a bicinchoninic acid assay (Pierce and Warriner UK Ltd, Ches-
ter, UK).
2.4. Mass spectrometry
The molecular weights of the K-toxin proteins were determined
using on-line liquid chromatography-electrospray ionisation mass
spectrometry. Puri¢ed protein (2 Wg) was diluted to 0.4 mg/ml in
0.1% tri£uoroacetic acid and loaded onto a HPLC column (Hew-
lett-Packard 1100, Waldbronn, Germany). The eluant was directed
to the electrospray ionisation source of a Quattro II tandem quadru-
pole mass spectrometer (Micromass UK Ltd, Altrincham, UK). Max-
Ent software (Micromass UK Ltd, Altrincham, UK) was used to
calculate the molecular weights of the K-toxin proteins.
2.5. CD spectroscopy analysis
Secondary structures of the puri¢ed proteins were determined using
circular dichroism spectroscopy (CD) in a Jasco J-720 spectropolarim-
eter at 25 þ 1‡C as described previously [17].
2.6. Phospholipase C and haemolytic activity
Phospholipase C activity of the puri¢ed proteins was determined
using 10% (v/v in 0.9% saline) egg yolk emulsion (Oxoid Ltd, Basing-
stoke, UK) or using p-nitrophenylphosphorylcholine (pNPPC) [17,18].
Membrane disrupting activity was determined using liposomes com-
posed of sphingomyelin and cholesterol and containing carboxy£uo-
rescein [17]. Haemolytic activity was measured using 5% (v/v) washed
mouse erythrocytes [18].
2.7. Cytotoxicity and myotoxicity
Cytotoxicity towards the Chinese hamster ¢broblast mutant cell line
Don Q was measured as detailed previously [7]. Results are expressed
as the percentages of neutral red uptake in control wells incubated
without toxin. Myotoxicity was measured as creatine kinase (CK) (EC
2.7.3.2) released to the plasma 3 h after injection of 1.5 Wg of the
K-toxin proteins (in 50 Wl of phosphate-bu¡ered saline) in the right
gastrocnemius muscle in groups of eight Swiss^Webster mice [7]. CK
activity was determined using a kinetic assay (Sigma, CK-10).
2.8. Ca2+ dependence
The relative mobility of K-toxin and the variant proteins was de-
termined in the absence and presence of Ca2 as described previously
[21]. A 0.5 Wg/ml protein solution was prepared in 10 mM Tris^HCl
pH 8.0 containing either 10 mM EDTA or 20 mM CaCl2. The sam-
ples were incubated at room temperature for 5 min and analysed
using native PAGE electrophoresis (8^25%, Amersham-Pharmacia
Fig. 1. Crystal structure of K-toxin with the putative membrane recognition interface shown uppermost. Residues which were modi¢ed in this
study (D269, Y331 and F334) are highlighted in green. Residues previously shown to play a role in haemolytic, cytotoxic and myotoxic activities
are shown in magenta.
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Biotech UK Ltd PhastSystem). One gel was stained with Coomassie
blue whilst the second was transferred onto a PVDF membrane and a
Western blot performed using a polyclonal antibody (mouse anti-K)
and detected using a goat anti-mouse IgG secondary antibody
(AuroProbe, Amersham-Pharmacia Biotech UK Ltd). The Western
blot was developed using an IntenSE kit (Amersham-Pharmacia Bio-
tech UK Ltd) according to the manufacturer’s instructions.
3. Results and discussion
3.1. Construction, puri¢cation and characterisation of
site-directed mutants
We have previously shown that di¡erences in the carboxy-
terminal domains of C. bifermentans Cbp and C. perfringens
K-toxin play a key role in determining the haemolytic and
cytotoxic activities of these phospholipases C [16,17]. To fur-
ther identify amino acid residues in the carboxy-terminal do-
mains which modulated haemolytic and cytolytic activities,
three site-directed mutants were constructed which would en-
code proteins in which the amino acid in K-toxin (D269, Y331
or F334 ; Fig. 1) was replaced with its counterpart from C.
bifermentans Cbp (Y, L and I respectively). The authenticity
of the mutated genes was veri¢ed by nucleotide sequencing of
the entire gene. The mutated genes were expressed in E. coli,
and the corresponding proteins isolated from the periplasmic
space of the bacteria and puri¢ed using ion exchange chroma-
tography.
Using electrospray mass spectrometry the molecular
weights of the wild-type and variant proteins were shown to
be similar to those predicted from the amino acid sequence
(K-toxin, 42 522 Da; K-toxin D269Y, 42 579 Da; K-toxin
Y331L, 42 473 Da; K-toxin F334I, 42 493 Da). Far-UV (180^
260 nm) CD spectra demonstrated that the secondary struc-
tures were similar for the mutants Y331L and F334I. However,
the variant D269Y showed lower intensities in both the pos-
itive and negative bands indicating that this substitution may
cause a destabilising e¡ect on the structure (Fig. 2).
3.2. Calcium binding properties of K-toxin variants
The residue D269 in K-toxin is proposed to play a role in
Ca2-mediated recognition of phospholipids. Its replacement
by Tyr, the counterpart from Cbp, would be expected to
modify the ability of the protein to bind Ca2 ions. Hammar-
berg et al. [21] have previously shown that native gel electro-
phoresis can be used to determine Ca2 binding by proteins,
since in the presence of Ca2 they migrate with greater mo-
bility. We have previously replaced another Ca2-co-ordinat-
ing residue (D293) in the carboxy-terminal domain of K-toxin
with serine and found that the variant D293S has a similar
mobility in the presence or absence of Ca2 ions [22]. The
relative mobility of the K-toxin variants generated in this
study in the presence of Ca2 was compared with mobility
in the presence of excess EDTA, to chelate Ca2 ions. The
mobility of wild-type K-toxin or the variants Y331L and F334I
was greater in the presence of Ca2. In contrast, the variant
D269Y migrated at a similar rate in the presence or absence of
Ca2 ions (Fig. 3), demonstrating that this amino acid sub-
stitution alters the ability of K-toxin to bind Ca2 ions.
3.3. Replacement of aspartate 269 with tyrosine
Although the ability of the variant D269Y to bind Ca2 was
reduced, the variant protein showed only a small reduction in
phospholipase C activity towards aggregated egg yolk phos-
pholipid (Fig. 4A) or pNPPC (Fig. 4B). Furthermore, its
membrane-disrupting activity towards sphingomyelin lipo-
somes and its myotoxic activity were a¡ected only slightly
(Fig. 4D,E). Surprisingly, variant D269Y showed enhanced
haemolytic and cytotoxic activities (Fig. 4C,F). This result
contrasts with the ¢nding that replacement of D269 with as-
paragine resulted in a marked reduction of haemolytic and
cytotoxic activity [7]. The crystal structure of K-toxin reveals
that D269 is located on the proposed membrane binding face
(Fig. 1), and it is predicted to play a role in Ca2-mediated
recognition of the phospholipid head group [13]. Tyrosine
residues are known to play key roles in the interfacial binding
of other protein to membranes [23^26]. It is possible that the
substitution of D269 with tyrosine would enhance the interac-
tion of the variant protein with the target cell membrane.
Fig. 2. Far-UV CD analysis of K-toxin, variant D269Y, variant
Y331L and variant F334I. Data were collected at 180^260 nm and
compared with wild-type K-toxin.
Fig. 3. Determination of Ca2 dependence of K-toxin mutants
D269Y, Y331L and F334I using native gel electrophoresis. Samples
were incubated with EDTA in the absence or presence of 20 mM
Ca2 and relative mobility determined. A: Lane 1 = molecular
weight markers, lane 2 =K-toxin+EDTA, lane 3 =K-toxin+
EDTA+20 mM Ca2, lane 4 = variant D269Y+EDTA, lane 5 = var-
iant D269Y+EDTA+20 mM Ca2. B: Lane 1 = molecular weight
markers, lane 2 = variant Y331L+EDTA, lane 3 = variant Y331L+
EDTA+20 mM Ca2, lane 4 = variant F334I+EDTA, lane 5 = variant
F334I+EDTA+20 mM Ca2.
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Therefore, the reduced ability of variant D269Y to bind Ca2
may have been o¡set by the enhanced ability of this protein to
interact with other regions of the membrane.
3.4. Replacement of tyrosine 331 with leucine
In comparison with the wild-type toxin, the replacement of
Y331 with leucine resulted in a two-fold reduction of activity
towards aggregated egg yolk phosphatidylcholine (Fig. 4A) or
towards sphingomyelin liposomes (Fig. 4D), but only a slight
reduction in activity towards pNPPC (Fig. 4B). However, in
comparison with the wild-type toxin, variant Y331L showed a
signi¢cant reduction in haemolytic, myotoxic and cytotoxic
activities (Fig. 4C,E,F). These ¢ndings demonstrate the role
of Y331 in the biological activities of K-toxin and indicate that
its substitution with leucine in Cbp contributes to the reduced
activities of this enzyme. In K-toxin, residue Y331 is located on
Fig. 4. Activity of puri¢ed wild-type K-toxin (WT) and variant D269Y, variant Y331L or variant F334I ; phospholipase C activity towards egg
yolk phospholipid (A) or pNPPC (B), haemolytic activity towards mouse erythrocytes (C), release of carboxy£uorescein from sphingomyelin
liposomes (D), myotoxicity in mice (E) or cytotoxicity towards Chinese hamster ¢broblast cells (F). Values shown are the mean of at least three
determinations (S.D. þ 0.1%).
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the proposed membrane binding face and its phenolic group is
surface-exposed [13]. The phenolic side chains of tyrosine res-
idues are known to play key roles in the anchoring of proteins
and peptides into phospholipid bilayers [25,26]. In the case of
lipase and phospholipase A2, tyrosine residues located on the
membrane recognition interface have been shown to be crit-
ical for interfacial binding [23,24]. It is possible that Y331 in
K-toxin also plays a important role in the interaction with the
target membrane.
3.5. Replacement of phenylalanine 334 with isoleucine
The substitution of F334 with isoleucine resulted in a reduc-
tion of the enzymatic activity towards aggregated egg yolk
phosphatidylcholine (Fig. 4A), but a slight enhancement in
activity towards pNPPC, in comparison with the wild-type
K-toxin (Fig. 4B). Furthermore, the variant F334I showed a
reduced membrane-disrupting activity towards sphingomyelin
liposomes (Fig. 4D), decreased haemolytic and myotoxic ac-
tivities (Fig. 4C,E) and a marked reduction (88-fold) in cyto-
toxic activity (Fig. 4F), in comparison with the wild-type
K-toxin. These ¢ndings show that F334 in K-toxin plays a
key role in conferring full toxicity and also demonstrate that
its substitution by isoleucine, which occurs naturally in the C.
bifermentans Cbp, contributes to the reduced haemolytic, cy-
totoxic and myotoxic activity of the latter enzyme. Like Y331,
residue F334 is located on the proposed membrane binding
face of K-toxin [13]. In proteins, such as pancreatic lipase
and snake venom phospholipases A2, phenylalanine residues
located on the interfacial binding surface play key roles in
membrane interaction because their hydrophobic side chains
become buried in the core of the lipid bilayer [23^25]. There-
fore, it is possible that the substitution of F334 by isoleucine in
K-toxin results in a reduced ability of the protein to interact
with the hydrocarbon tail groups of phospholipids, due to the
loss of this surface-exposed aromatic side chain.
3.6. Interactions with synthetic versus cellular membranes
In general, the patterns of activity of the variant proteins
towards murine erythrocytes and Chinese hamster ¢broblasts
were similar, although they did not correlate exactly with the
activity towards sphingomyelin liposomes. This ¢nding may
re£ect di¡erences in the membrane recognition event in the
di¡erent assays. There is evidence that the presence of gan-
gliosides in the target membrane modulates the interaction
with K-toxin [27,28]. Sphingomyelin liposomes lack these gly-
cosphingolipids and therefore the interaction of K-toxin with
these arti¢cial membranes might be di¡erent from that with
cellular membranes. Also, endogenous membrane phospholi-
pases, which are activated in eukaryotic cells exposed to K-
toxin, are thought to make a signi¢cant contribution to mem-
brane damage [10^12] amplifying any e¡ects due to the action
of K-toxin. These endogenous enzymes would not be present
in liposomes which might also explain their reduced sensitivity
to the action of K-toxin. The myotoxic activity of the variant
proteins showed only a partial correlation with their haemo-
lytic and cytotoxic activities. This could be explained because
the pathogenesis of the myotoxicity depends not only on the
direct destruction of the muscle ¢bre membranes, but also on
the ability of the toxin to induce the formation of intravas-
cular thrombi, with a resultant reduction in blood £ow and
increased tissue anoxia [7,8].
The results presented here have shown that the substitution
of a single amino acid residue within the carboxy-terminal
domain of K-toxin was not su⁄cient to completely abolish
the haemolytic or cytotoxic activity. However, the results
clearly demonstrate that residues Y331 and F334 play key roles
in conferring these activities on K-toxin. Furthermore, the
data also indicate that the substitutions of these residues,
which occur in Cbp, contribute to explain the reduced hae-
molytic and cytotoxic activity of this enzyme.
The variants investigated in this study add signi¢cantly to
the previous studies in which 14 other residues in the carboxy-
terminal domain of K-toxin have been substituted [7,22,29,30].
These studies indicate that mutations which modulate the
haemolytic, cytotoxic or myotoxic activities of K-toxin are
located primarily on the putative membrane binding face of
the carboxy-terminal domain (Fig. 1). The exceptions to this
are residue T272, where the mutation to proline is likely to
cause a gross structural destabilisation [30], and residue
D305, which is thought to play a role in communication of
the amino- and carboxy-terminal domains [22]. Overall these
¢ndings support the model that surface-exposed hydrophobic
amino acids and calcium-mediated phospholipid binding are
both essential for binding of the carboxy-terminal domain of
K-toxin to cell membranes [13,14].
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